| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
3-Fluoro-L-tyrosine targets tyrosine aminotransferase (TAT), inhibiting transamination by this enzyme. As a tyrosine analogue, it can be biologically incorporated into proteins in place of tyrosine. The compound's fluorine substitution provides unique properties for biochemical analysis, making it useful for studying protein structure and function. Its targets include enzymes involved in tyrosine metabolism, particularly tyrosine aminotransferase. The compound is also used in positron emission tomography (PET) for cancer detection.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 3-Fluoro-L-tyrosine inhibits transamination by tyrosine aminotransferase (TAT). The compound has been shown to be biologically incorporated into proteins in place of tyrosine. Its fluorine substitution provides unique properties for biochemical analysis. The compound is soluble in water (9.8 g/L) and serves diverse applications in synthetic biology and metabolic engineering. These in vitro findings support its applications in protein biochemistry and metabolic research.
|
| ln Vivo |
In vivo studies of 3-Fluoro-L-tyrosine have focused on its use in positron emission tomography (PET) for cancer detection. As a fluorinated amino acid analogue, it can be used as a radiotracer for imaging purposes. The compound's incorporation into proteins in vivo allows for the study of protein synthesis and turnover. However, comprehensive in vivo pharmacological studies specifically targeting 3-Fluoro-L-tyrosine as a therapeutic agent are not well documented. The compound is intended for research use only.
|
| Enzyme Assay |
In vitro enzyme assays for 3-Fluoro-L-tyrosine typically involve testing its inhibition of tyrosine aminotransferase (TAT). Enzyme activity is measured by monitoring the transamination reaction in the presence of varying concentrations of the compound. The compound's purity (≥98.0%) and identity are confirmed using analytical chemistry methods such as high-performance liquid chromatography, nuclear magnetic resonance spectroscopy, and mass spectrometry. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for 3-Fluoro-L-tyrosine involve culturing cells to evaluate its incorporation into proteins in place of tyrosine. Cells are treated with varying concentrations of the compound and protein synthesis is assessed. For PET imaging studies, cells are treated with radiolabeled compound and uptake is measured. Cell viability is assessed using MTT or similar colorimetric assays. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for 3-Fluoro-L-tyrosine are conducted for PET imaging studies in cancer research. Animals are administered the radiolabeled compound and imaging is performed to detect tumors. Parameters assessed include tumor uptake, biodistribution, and clearance. For metabolic studies, animals are administered the compound and tyrosine metabolism is assessed. Control groups receiving vehicle alone are included for comparison. All procedures comply with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 3-Fluoro-L-tyrosine reflect its nature as a fluorinated amino acid. It has a molecular weight of 199.18 and the molecular formula C9H10FNO3. The compound appears as a white to light gray to light yellow powder and is soluble in water (9.8 g/L). It is stored at room temperature in a cool and dark place. As an amino acid analogue, it would be transported into cells via amino acid transporters and metabolized through standard amino acid pathways.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3-Fluoro-L-tyrosine has been evaluated in the context of its use as a research chemical. The compound has a purity of ≥98.0%. Proper handling procedures including keeping container tightly closed and storing away from oxidizing agents are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile for pharmaceutical applications.
|
| References |
[1]. Iron A, et al. Action of the phosphonic analogue of tyrosine and of other tyrosine derivatives on rat liver tyrosine aminotransferase. Amino Acids. 1993 Feb;5(1):33-7.
[2]. Phillips RS, et al. Effects of tyrosine ring fluorination on rates and equilibria of formation of intermediates in the reactions of carbon-carbon lyases. Eur J Biochem. 1997 Mar 1;244(2):658-63. |
| Additional Infomation |
3-Fluoro-L-tyrosine is a 3-fluorotyrosine derivative, belonging to the L-tyrosine family, and is a non-protein L-α-amino acid. 3-Fluoro-L-tyrosine is a solid. This compound belongs to the phenylpropionic acid class of compounds. These compounds contain a benzene ring conjugated with propionic acid in their structure. 3-Fluoro-L-tyrosine targets mitochondrial superoxide dismutase [mn]. See also: 3-Fluorotyrosine (note moved to).
3-Fluoro-L-tyrosine (CAS# 7423-96-3) is a fluorinated analogue of the amino acid tyrosine with the molecular formula C9H10FNO3 and a molecular weight of 199.18. It is characterized by fluorine substitution at the third position of the benzene ring. The compound inhibits transamination by tyrosine aminotransferase (TAT) and can be biologically incorporated into proteins in place of tyrosine. It is used in positron emission tomography (PET) for cancer detection. The compound is soluble in water and has a purity of ≥98.0%. |
| Molecular Formula |
C9H10FNO3
|
|---|---|
| Molecular Weight |
199.18
|
| Exact Mass |
199.064
|
| CAS # |
7423-96-3
|
| PubChem CID |
643330
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
260-261°C
|
| Flash Point |
>110°C
|
| Index of Refraction |
-9 ° (C=1, 1mol/L HCl)
|
| LogP |
1.186
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
212
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1=C(C=CC(=C1)C[C@@H](C(=O)O)N)O
|
| InChi Key |
VIIAUOZUUGXERI-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C9H10FNO3/c10-6-3-5(1-2-8(6)12)4-7(11)9(13)14/h1-3,7,12H,4,11H2,(H,13,14)/t7-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(3-fluoro-4-hydroxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0206 mL | 25.1029 mL | 50.2058 mL | |
| 5 mM | 1.0041 mL | 5.0206 mL | 10.0412 mL | |
| 10 mM | 0.5021 mL | 2.5103 mL | 5.0206 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
